Intrinsiqs

Is First Tracks Biotherapeutics Inc overvalued?

First Tracks Biotherapeutics Inc (TRAX) — key valuation metrics and fundamentals.

No verdict
Price
$19.59
Fair value
Current P/E
Normal P/E
Market cap
$619.7M
Dividend yield
Return on equity
Sector
Healthcare

See the full interactive analysis →

Fair value compares TRAX's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 30 Jun 2026.